By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, often expressed on tumor cells and other immune-regulatory cells within the tumor microenvironment (TME), camrelizumab effectively reverses the immune suppression camrelizumab effectively reverses immune suppression and reactivates exhausted T lymphocytes, thereby promoting a robust antitumor immune response[29,45]. The gene discussed is PDCD1LG2; the disease is neoplasm.